Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma
Mené sur 46 patients âgés de moins de 30 ans et atteints d'un lymphome hodgkinien réfractaire ou récidivant, cet essai de phase I/II évalue la dose maximale tolérée, l'efficacité, du point de vue de la proportion de patients ayant atteint une réponse complète, et la toxicité du brentuximab védotin en combinaison avec la gemcitabine
Hodgkin's lymphoma is a disease that mainly affects paediatric and young adult patients. The young age of the patients makes recurrence of the disease an especially dramatic event. However, successful treatment for relapsed or refractory Hodgkin's lymphoma is still an unmet medical need. The main objective of salvage treatment is the achievement of complete remission, in order to perform consolidation treatment with autologous stem cell transplantation, which is the standard second-line treatment. The promising results as a single agent and the manageable safety profile of brentuximab vedotin, a monoclonal anti-CD30 antibody drug conjugated with monomethyl auristatine E, makes it an ideal backbone of the salvage treatment in Hodgkin's lymphoma, and some combination regimens with brentuximab vedotin have been reported and are available in the salvage setting
The Lancet Oncology , commentaire, 2017